Blincyto (blinatumomab) is used to treat a certain type of acute lymphoblastic leukemia in adults and children.
Blincyto is given after other cancer treatments have been tried without success.
Blincyto was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.
Acute lymphoblastic leukemia is a cancer of the blood in which a particular kind of white blood cell is growing out of control.
